

## Disclosures

### Management guidelines for HIV-related Co-morbidities Result in Increased Screening but no change in Primary Prevention Implementation

Trevillyan JM, Dart A, Topliss DJ, Walker RG, Whiting SE, Hoy JF


ASHM Friday 18<sup>th</sup> September 2015



- No authors have any significant conflicts of interest relevant to this work
- Professor Jennifer Hoy's institution has received reimbursement for her participation in Advisory Boards for Gilead Science, Merck Sharp & Dohme, ViiV Healthcare and Abbott.

## Background


- Serious non-AIDS events are of increasing importance in the modern antiretroviral era



Rodger et al. *AIDS* 2013;27(6):973




## The changing demographic of HIV infection



Smit et al. *Lancet ID* 2015; 15:810-18




## "Multi-morbidity" will be increasingly common



Smit et al. *Lancet ID* 2015; 15:810-18



## Decreasing rates of AMI over time in HIV+ patients



Klein et al. *CID* 2015;60(8):1278




## Aims

- Audit compliance with national guidelines for the screening and management of cardiovascular risk at a tertiary referral centre for HIV care
- Determine if simplified clinical management guidelines and education strategies could improve screening and management in HIV positive individuals



## Timeline of study



## HIV Service Guidelines

### Screening and Management of HIV related Co-Morbidities



## Development of clinical guidelines

- Writing panel included:
  - HIV physicians
  - Cardiologist
  - Endocrinologist
  - Renal Physician
  - General medical Physician
  - HIV Specialist Dietitian
  - HIV specialist Pharmacist
- Release coincided with weekly brief education sessions for ID physicians
- Guidelines available in electronic and hard copy format in the clinic consulting rooms



## Details of Audit completion

- Two unique groups of 100 consecutive HIV positive outpatients who attend the Department of Infectious diseases at the Alfred Hospital for routine HIV care were compared
- Data was collected retrospectively from the electronic medical record and pathology systems
- Results that had been recorded in the 24 months prior to the date of audit were included
- The most recent result was kept in those who had multiple recordings over that period

**Hypertension in HIV**

Who to Screen	Frequency	How to screen
All HIV positive patients	Annually, immediately prior to starting ART and Q12 prior any change in ART	Patients listed for care, outpatients, ID, GPs, and endocrinologists

**Lifestyle Advice - Should be highlighted in ALL patients**

**Dietary Counselling**

**Exercise**

**LIPID TARGETS ON THERAPY**

Target	LDL-C	LDL-C	LDL-C
Total Cholesterol (TC)	< 160 mg/dL	< 160 mg/dL	< 160 mg/dL
LDL-C	< 100 mg/dL	< 100 mg/dL	< 100 mg/dL
LDL-C	< 100 mg/dL	< 100 mg/dL	< 100 mg/dL
LDL-C	< 100 mg/dL	< 100 mg/dL	< 100 mg/dL

**Daily Drug Orders\***

Agent	Starting dose	Titration	Comments
Atorvastatin	20mg	40mg	Check for myopathy (e.g. creatine kinase) and myalgia. Stop if severe.
Rosuvastatin	20mg	40mg	Check for myopathy (e.g. creatine kinase) and myalgia. Stop if severe.
Simvastatin	20mg	40mg	Check for myopathy (e.g. creatine kinase) and myalgia. Stop if severe.
Fish Oil	1-2g	2-3g	No adjustment required
ezetimibe	10mg	No adjustment required	Monitor ALT/AST if combination with statins. If rise of side effects, check liver function tests. Stop if ALT/AST > 3x ULN.

**Flowchart: Does the patient have any of the following?**

```

    graph TD
        A[Does the patient have any of the following?] --> B{10-19%}
        A --> C{20-29%}
        A --> D{30-39%}
        A --> E{40-49%}
        A --> F{50-59%}
        A --> G{60-69%}
        A --> H{70-79%}
        A --> I{80-89%}
        A --> J{90-99%}
        A --> K{100%}
        
        B --> L[Start statin]
        C --> L
        D --> L
        E --> L
        F --> L
        G --> L
        H --> L
        I --> L
        J --> L
        K --> L
        
        L --> M[Check ALL on every visit (at least 4 weeks)]
        M --> N{Achieved target LDL and total cholesterol?}
        N --> O{No}
        N --> P{Yes}
        
        O --> Q{What statin dose used?}
        Q --> R{Increase statin dose}
        R --> M
        
        P --> S{Achieved target TG level?}
        S --> T{No}
        S --> U{Yes}
        
        T --> V{Consider adding ezetimibe}
        V --> W{Add Ezetimibe}
        W --> M
        
        U --> X{Consider adding Fibrates}
        X --> Y{Add Fibrates}
        Y --> M
        
        M --> Z[Refer to Complex Care HIV metabolic clinic if unable to reach targets or drug intolerances]
    
```



## Definition: Recommended Statin Therapy

- The National Vascular Disease Prevention Alliance (NVDPA); [www.cvdcheck.org.au](http://www.cvdcheck.org.au)
- Any patient (regardless of cholesterol) with:
  - Coronary artery disease
  - Peripheral vascular disease
  - Stroke
  - Chronic kidney impairment (eGFR < 45ml/min)
  - Absolute risk score > 15%
  - Diabetes if > 60 years old
  - Total cholesterol > 7.5 mmol/L
  - Persistent hypertension (SBP ≥ 180 mmHg)



## Definition: Recommended Statin Therapy

- Any patient with risk score 10 -15% AND:
  - Family history of coronary artery disease in 1<sup>st</sup> degree relative
  - Persistent hypertension ≥ 160mmHg
  - Aboriginal descent

### Inadequate statin therapy

- Patient currently receiving statin therapy and total cholesterol >4.0 mmol/L, *or*
- Patient inappropriately not on a statin



## Statistical Methods

- Results were summarized by group using Fisher's exact or chi-squared tests as appropriate
- Mann Whitney U test for continuous data
- Continuous variables described as medians and interquartile ranges
- All statistical analyses performed on Stata 11.0/IC (College Station, Texas)
- The project was approved by the Alfred Ethics committee (Project Number 167-13)




## Participant Characteristics

	Pre Intervention
n	100
Male	93 (93%)
Age, years	49 (38 - 55)
Smoking status	
Never smoked	24 (24%)
Ex-Smoker	5 (5%)
Current Smoker	38 (38%)
Not documented	33 (33%)
Diabetic status	
Non-diabetic	58 (58%)
Diabetic	6 (6%)
Not screened	36 (36%)
History of CVD <sup>a</sup>	7 (7%)
Framingham Risk score, %	10 (6.5 - 13)
eGFR, ml/min	85 (75 - >90)
Blood pressure recorded	65 (65%)
Systolic BP, mmHg	125 (120 - 132)




## Cholesterol


- 81% pre and 83% post-intervention had fasting cholesterol levels available (p = 0.713)



## Compliance with guidelines for statin use



## Adequacy of Statin Therapy




MONASH University



## Management of Hypertension

- 23 participants pre-intervention and 17 post intervention were receiving an antihypertensive


Patients with SBP  $\geq$  140mmHg



MONASH University




## Mean Systolic Blood Pressure



MONASH University



## High proportion of patients with borderline renal function as estimated by eGFR



MONASH University



## Limitations

- Small sample size
- Retrospective design
- Homogeneous patient population
- Potentially not long enough between intervention and post-audit for lipid or blood pressure changes to take effect
- Equally the durability of improved attention to screening for cardiovascular risk factors post intervention is not known

MONASH University



## Conclusions

- Improvements in screening for cardiovascular risk factors can be achieved with education tools
- These alone are not sufficient to improve the implementation or optimisation of primary preventative therapies
- Changes to the model of HIV care provision may be what's needed

MONASH University



## Acknowledgements

---

- J Trevillyan was supported by an Australian Postgraduate Award
- An abbreviated version of this data was published in *AIDS* 2015;29 :745

[Janine.Trevillyan@monash.edu](mailto:Janine.Trevillyan@monash.edu)

